WARNING: RISK OF MEDICATION ERRORS DUE TO INCORRECT ROUTE OF ADMINISTRATION CYKLOKAPRON is for intravenous use only. Serious, including fatal, adverse reactions including seizures and cardiac arrythmias have occurred when CYKLOKAPRON was inadvertently administered via the neuraxial route [see Warnings and Precautions (5.1)].
WARNING: RISK OF MEDICATION ERRORS DUE TO INCORRECT ROUTE OF ADMINISTRATION See full prescribing information for complete boxed warning. CYKLOKAPRON is for intravenous use only. Serious, including fatal, adverse reactions including seizures and cardiac arrythmias have occurred when CYKLOKAPRON was inadvertently administered intrathecally via the neuraxial route.
(5.1)
Use: Labeled indications
- CYKLOKAPRON ® is indicated in patients with hemophilia for short-term use (2 to 8 days) to reduce or prevent hemorrhage and reduce the need for replacement therapy during and following tooth extraction.
Full indications and usage US FDA label
1 INDICATIONS AND USAGE CYKLOKAPRON ® is indicated in patients with hemophilia for short-term use (2 to 8 days) to reduce or prevent hemorrhage and reduce the need for replacement therapy during and following tooth extraction. CYKLOKAPRON is an antifibrinolytic indicated in patients with hemophilia for short-term use (2 to 8 days) to reduce or prevent hemorrhage and reduce the need for replacement therapy during and following tooth extraction. (1)
Contraindications
4 CONTRAINDICATIONS CYKLOKAPRON Injection is contraindicated:
- As a neuraxial (i.e., intrathecal, epidural) injection [see Warnings and Precautions (5.1)].
- In patients with subarachnoid hemorrhage. Anecdotal experience indicates that cerebral edema and cerebral infarction may be caused by CYKLOKAPRON in such patients.
- In patients with active intravascular clotting [see Warnings and Precautions (5.2)].
- In patients with hypersensitivity to tranexamic acid or any of the ingredients [see Warnings and Precautions (5.4)].
- As a neuraxial (i.e., intrathecal, epidural) injection. (4)
- In patients with subarachnoid hemorrhage, due to risk of cerebral edema and cerebral infarction. (4)
- In patients with active intravascular clotting. (4)
- In patients with severe hypersensitivity reactions to tranexamic acid or any of the ingredients. (4)
Dosing: Adult
- • Before Extraction: Administer 10 mg/kg actual body weight of CYKLOKAPRON intravenously with replacement therapy as a single‑dose. (2.1)
- • After Extraction: Administer 10 mg/kg actual body weight of CYKLOKAPRON intravenously 3 to 4 times daily for 2 to 8 days. (2.1)
- • Infuse undiluted solution no more than 1 mL/minute to avoid hypotension. (2.3)
- • Reduce the dosage for patients with renal impairment. (2.2, 8.6)
2.1 Recommended Dosage
2.1 Recommended Dosage The recommended dose of CYKLOKAPRON is 10 mg/kg actual body weight administered as a single intravenous dose immediately before tooth extractions. Following tooth extraction, CYKLOKAPRON may be administered at a dose of 10 mg/kg actual body weight intravenously 3 to 4 times daily for 2 to 8 days.
2.2 Recommended Dosage for Patients With Varying Degrees of Renal Impairment
2.2 Recommended Dosage for Patients With Varying Degrees of Renal Impairment For patients with moderate to severe impaired renal function, the following dosages are recommended: Table 1. Recommended Dosage in Patients With Varying Degrees of Renal Impairment Dose reduction is recommended for all doses, both before and after tooth extraction.
Serum Creatinine (mg/dL) CYKLOKAPRON Dosage 1.36 mg/dL to 2.83 mg/dL 10 mg/kg intravenously twice daily 2.83 mg/dL to 5.66 mg/dL 10 mg/kg intravenously daily >5.66 mg/dL 10 mg/kg intravenously every 48 hours or 5 mg/kg intravenously every 24 hours
2.3 Preparation and Administration
2.3 Preparation and Administration CYKLOKAPRON is for intravenous administration only. CYKLOKAPRON can be administered undiluted or as a diluted solution.
- Use aseptic technique to prepare CYKLOKAPRON.
- Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. CYKLOKAPRON is a clear and colorless solution. Discard the vial if particulate matter is observed.
- Calculate the dose (mg) based on the patient’s actual body weight and the total volume (mL) of CYKLOKAPRON solution required. If diluting CYKLOKAPRON, follow the instructions below:
- From the diluent infusion bag, withdraw a volume equal to the volume of the CYKLOKAPRON solution required for the patient’s dose.
- Withdraw the required volume of CYKLOKAPRON solution from the vial and dilute with a compatible diluent (see below) to make a final concentration of 10 mg/mL or 20 mg/mL. Discard any unused portion left in the vial. o For intravenous infusion, CYKLOKAPRON Injection may be mixed with most solutions for infusion such as electrolyte solutions, carbohydrate solutions, amino acid solutions, and Dextran solutions. o Heparin may be added to CYKLOKAPRON Injection. o CYKLOKAPRON Injection should NOT be mixed with blood. o The drug is a synthetic amino acid and should NOT be mixed with solutions containing penicillin.
- Gently invert the infusion bag to mix the diluted solution. DO NOT SHAKE.
- If not used immediately, store the diluted CYKLOKAPRON infusion solution at room temperature 20ºC to 25°C (68ºF to 77°F) for up to 4 hours. Administration Infuse undiluted solution no more than 1 mL/minute to avoid hypotension [see Adverse Reactions (6.2)]. Administer the undiluted and diluted solutions intravenously according to Table 2. Table 2. Administration Rates for Undiluted and Diluted Solutions Undiluted solution Diluted solution Final concentration 100 mg/mL 10 mg/mL 20 mg/mL Administration rate 0.5 mL/minute (no more than 1 mL/minute) 5 mL/minute 2.5 mL/minute
Dosing: Altered kidney function
2.2 Recommended Dosage for Patients With Varying Degrees of Renal Impairment For patients with moderate to severe impaired renal function, the following dosages are recommended: Table 1. Recommended Dosage in Patients With Varying Degrees of Renal Impairment Dose reduction is recommended for all doses, both before and after tooth extraction. Serum Creatinine (mg/dL) CYKLOKAPRON Dosage 1.36 mg/dL to 2.83 mg/dL 10 mg/kg intravenously twice daily 2.83 mg/dL to 5.66 mg/dL 10 mg/kg intravenously daily >5.66 mg/dL 10 mg/kg intravenously every 48 hours or 5 mg/kg intravenously every 24 hours
8.6 Renal Impairment Reduce the dosage of CYKLOKAPRON in patients with renal impairment, based on the patient's serum creatinine [see Dosage and Administration (2.2), Clinical Pharmacology (12.3)].
Patients with Renal Impairment The blood levels of tranexamic acid are increased in patients with renal insufficiency. Urinary excretion following a single intravenous injection of tranexamic acid declines as renal function decreases. Following a single 10 mg/kg intravenous injection of tranexamic acid, the 24-hour urinary fractions of tranexamic acid with serum creatinine concentrations 1.4 – 2.8, 2.8 – 5.7, and greater than 5.7 mg/dL were 51, 39, and 19%, respectively.
The 24-hour tranexamic acid plasma concentrations for these patients demonstrated a direct relationship to the degree of renal impairment. Therefore, dose adjustment is needed in patients with renal impairment [see Dosage and Administration (2.2), Use in Specific Populations (8.6)].
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosing: Pediatric
Pediatric use (US label) US FDA label
8.4 Pediatric Use There are limited data concerning the use of CYKLOKAPRON in pediatric patients with hemophilia who are undergoing tooth extraction. The limited data suggest that there are no significant pharmacokinetic differences between adults and pediatric patients.
Dosing: Older adult
Geriatric use (US label) US FDA label
8.5 Geriatric Use Clinical studies of CYKLOKAPRON did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function.
Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function [see Dosage and Administration (2.2), Clinical Pharmacology (12.3)].
Administration
2.3 Preparation and Administration CYKLOKAPRON is for intravenous administration only. CYKLOKAPRON can be administered undiluted or as a diluted solution. • Use aseptic technique to prepare CYKLOKAPRON. • Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. CYKLOKAPRON is a clear and colorless solution. Discard the vial if particulate matter is observed. • Calculate the dose (mg) based on the patient’s actual body weight and the total volume (mL) of CYKLOKAPRON solution required. If diluting CYKLOKAPRON , follow the instructions below: • From the diluent infusion bag, withdraw a volume equal to the volume of the CYKLOKAPRON solution required for the patient’s dose. • Withdraw the required volume of CYKLOKAPRON solution from the vial and dilute with a compatible diluent (see below) to make a final concentration of 10 mg/mL or 20 mg/mL. Discard any unused portion left in the vial. o For intravenous infusion, CYKLOKAPRON Injection may be mixed with most solutions for infusion such as electrolyte solutions, carbohydrate solutions, amino acid solutions, and Dextran solutions. o Heparin may be added to CYKLOKAPRON Injection. o CYKLOKAPRON Injection should NOT be mixed with blood. o The drug is a synthetic amino acid and should NOT be mixed with solutions containing penicillin. • Gently invert the infusion bag to mix the diluted solution. DO NOT SHAKE. • If not used immediately, store the diluted CYKLOKAPRON infusion solution at room temperature 20ºC to 25°C (68ºF to 77°F) for up to 4 hours. Administration Infuse undiluted solution no more than 1 mL/minute to avoid hypotension [see Adverse Reactions (6.2) ]. Administer the undiluted and diluted solutions intravenously according to Table 2. Table 2. Administration Rates for Undiluted and Diluted Solutions Undiluted solution Diluted solution Final concentration 100 mg/mL 10 mg/mL 20 mg/mL Administration rate 0.5 mL/minute (no more than 1 mL/minute) 5 mL/minute 2.5 mL/minute
US FDA labelDosage forms
Philippines
- ) solution for injection: 50 mg/mL (250 mg/5 mL, 100 mg/mL (250 mg/2.5 mL, 100 mg/mL (500 mg/5 mL, 100 mg/mL (500 mg/mL, 500 mg/5 mL (100 mg/mL
- Solution for injection: 50 mg/mL, 100 mg/mL, 500 mg/5 mL
- Capsule: 250 mg, 500 mg
- Film-coated tablet: 500 mg
- ) solution for intravenous injection: 100 mg/mL (500 mg/5 mL
- ) solution fo injection: 100 mg/mL (500 mg/mL
- ) solution for injection i.v: 50 mg/mL (250 mg/50 mL
- ) solution for intravenous: 500 mg/5 mL (100 mg/mL
- )solution for injection: 100 mg/mL (500 mg/5 mL
- Mg/ml solution for injection: 100 mg/mL
and 2 more forms; see the products table.
Registered products in the Philippines
156 products registered with the Food and Drug Administration (FDA) Philippines list Tranexamic acid as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products156
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
ActranexTranexamic Acid | 100 mg/mL (500 mg/5mL) Solution for Intravenous InjectionUSP Type 1 Flint Glass Ampoule x 5 mL (Box of 5's) | Rx | Gufic Biosciences LimitedIndia | The Cathay Drug Co., Inc.Importer: Suhitas Pharmaceuticals Inc. | DRP-5237-01 | Apr 7, 2027 | |
ActranexTranexamic acid | 500 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 30's) | Rx | Globela Pharma Private LimitedIndia | The Cathay Drug Co., Inc.Importer: AMB HK Enterprises Inc. | DRP-12770-01 | Oct 6, 2027 | |
ActranexTranexamic Acid | 500 mg/5 mL (100 mg/mL) Solution for InjectionLow Borosilicate Glass Ampoule x 5mL in PVC tray (Box of 5's) | Rx | Reyoung Pharmaceutical Co., Ltd.China | The Cathay Drug Co., Inc. | DR-XY48398 | Oct 4, 2027 | |
ActranexTranexamic Acid | 500mg Film-Coated TabletAlu/PVC blister pack x 10's (Box of 30's) | Rx | Globela Pharma Private LimitedIndia | AMB HK Enterprises Inc. | DRP-12770 | Oct 6, 2027 | |
AmptrexTranexamic Acid | 50 mg/mL Solution for Injection (I.M/I.V.)USP Type I Amber Glass Ampoule x 5 mL (Box of 10's) | Rx | — | Steinbach Products, Inc. | DRP-4093 | Nov 20, 2027 | |
AncloticTranexamic Acid | 100 mg/mL (500 mg/5 mL) Solution for Intravenous InjectionUSP Type I Flint Glass Ampoule x 5 mL (Box of 5's) | Rx | Gufic Biosciences LimitedIndia | Suhitas Pharmaceuticals Inc. | DRP-5237 | Apr 7, 2027 | |
AneptilTranexamic Acid | 500mg/5mL Solution for Injection | Rx | — | Importer: West Wing Pharma Sales Inc. | DRP-3418 | Dec 6, 2026 | |
ANEXATranexamic Acid | 100 mg/mL (500 mg/5 mL) Solution for Injection (IV)Type I Clear Colorless Glass Ampoule x 5 mL (as net content) in Plastic Tray (Box of 5’s) | Rx | UNIJULES LIFE SCIENCES LIMITEDIndia | BELLUS LIFE SOLUTIONS, INC.Importer: AGLOBAL CARE, INC. | DRP-8687-01 | May 20, 2029 | |
ArmatraxTranexamic Acid | 100 mg/mL (500 mg/5 mL) Solution for Injection (IV)Type I Colorless Glass Ampoule x 5 mL (Box of 10's) | Rx | Union Korea Pharm Co., LtdKorea | Importer: H & B Pharma International Inc. | DRP-10924 | Dec 17, 2026 | |
ArmaxenicTranexamic Acid | 50mg/mL (250mg/5mL) Solution For Injection (IM/IV)USP Type I clear glass ampoule x 5 mL in plastic tray x 10's (Box of 10's) | Rx | Union Korea Pharm Co., LtdKorea | H & B Pharma International Inc. | FDA-0592706 | Jun 6, 2028 | |
BetranexTranexamic Acid | 500 mg/5 mL Solution for Injection (I.M./I.V.) | Rx | Alina Combine Pharmaceutical (Pvt.) Ltd. | — | DRP-3418-01 | Dec 6, 2026 | |
ClotranexTranexamic Acid | 100 mg/mL Solution for Injection (IV)10 mL USP Type I clear glass ampoule (Box of 1's) | Rx | Gland Pharma LimitedIndia | Pharma-Surrey International, Inc. | DRP-14862 | Jan 25, 2029 | |
ClottinexTranexamic Acid | 500 mg CapsuleAlu/Clear PVC Blister Pack x 10's (Box of 100's) | Rx | Lloyd Laboratories, Inc.Philippines | Rilem Pharma Corp.Trader: Eadriex Pharmaceuticals, Phils., Inc. | DRP-721 | Oct 5, 2031 | |
CuraclotTranexamic Acid | 500 mg Film-Coated TabletAlu/Alu Blister Pack of 10's (Box of 100's) | Rx | Healer's Lab. Unit IIIndia | Curasave PharmaImporter: Pharmakon Biotec Inc. | DRP-5424-01 | Aug 5, 2029 | |
CyclotraxTranexamic Acid | 100 mg/mL Solution for Injection (I.M./I.V.)Clear and Colorless Glass Ampoule x 5mL (Box of 10's) | Rx | Shin Poong Pharmaceutical Co., LtdRepublic of Korea | Phil. Pharmawealth, Inc. | DR-XY23884 | Feb 20, 2028 | |
CycloxidTranexamic Acid | 100 mg/mL Solution for Injection (IV)Type I Clear Colorless Glass Ampoule x 5 mL (Box of 5’s) | Rx | Jiangsu Ruinian Qianjin Pharmaceutical Co., Ltd.China | Global PharmatradeTrader: Mecechem (Wuxi) CO., Ltd. | DR-XY45004 | Jan 22, 2031 | |
CycloxidTranexamic Acid | 50 mg/mL (250 mg/50 mL) Solution For Injection I.VLow borosilicate glass ampoule x 5 mL (Box of 5's) | Rx | Reyoung Pharmaceutical Co., Limited.China | Global Pharmatrade | DRP-19122 | Oct 29, 2031 | |
DostanTranexamic Acid | 100 mg/mL (500 mg/5 mL) Solution for Intravenous InjectionUSP Type I Flint Glass Ampoule x 5 mL (Box of 5's) | Rx | Gufic Biosciences LimitedIndia | Heltker A.G. CorporationImporter: Ambica International Corporation | DRP-5172-07 | Feb 13, 2029 | |
DostanTranexamic Acid | 500 mg Film-Coated TabletBlister Pack x 10's (Box of 100's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Heltker A.G. Corporation | DR-XY30225 | Nov 5, 2029 | |
EpitraxTranexamic Acid | 100mg/mL Solution for Injection (IV)Type I Clear Glass Ampoule x 5mL (Box of 5' and 10's) | Rx | Scott-Edil Pharmacia LimitedIndia | Epione Lifecare Inc.Importer: Despina Pharma Inc. | DRP-14765-03 | Dec 29, 2028 | |
ExaclotTranexamic Acid | 100 mg/mL (500 mg/5 mL) Solution for Injection (IM/IV)5 mL USP Type I Clear, Colorless Glass Ampoule (Box of 10's) | Rx | Friends Pharma (Pvt.) Ltd.Pakistan | Exa Life Care Pharma Inc.Importer: Raquel-Abbas Pharmaceuticals & General Merchandise | DRP-9087-03 | Feb 19, 2029 | |
ExaclotTranexamic Acid | 100 mg/mL (500 mg/5 mL) Solution for Injection (IM/IV)5 mL USP Type I Clear, Colorless Glass Ampoule (Box of 10's) | Rx | Friends Pharma (Pvt.) Ltd.Pakistan | Exa Life Care Pharma Inc.Importer: Raquel-Abbas Pharmaceuticals & General Merchandise | DRP-9087-04 | Feb 19, 2029 | |
ExzamixxTranexamic Acid | 100 mg/mL (500 mg/5 mL) Solution for Intravenous (I.V.) InjectionUSP Type I clear glass ampoule with tray x 5 mL (Box of 10's) | Rx | Makcur Laboratories LimitedIndia | Ambica International CorporationImporter: Diafarm Inc. | DRP-11560-01 | Mar 30, 2037 | |
FERXAMICTranexamic Acid | 500 mg CapsulePVC Blister Pack x 10's (Box of 30's and 100's) | Rx | Azarias Pharmaceutical Laboratories Inc.Bulacan | Ferma Drug Enterprises | DRP-4204-06 | Feb 8, 2028 | |
FurenexTranexamic Acid | 500 mg/5mL (100 mg/mL) Solution For Injection (Im/Iv)Clear colorless glass ampoule x 5 mL (Box of 5's) | Rx | Furen Pharmaceutical Group Co., Ltd.China | Euro-Care Products Philippines | DRP-15310 | Nov 4, 2031 | |
GenexTranexamic Acid | 100 mg/mL (500 mg/5 mL) Solution for Injection (IM/IV)USP Type I clear glass ampoule x 5 mL in PVC plastic tray (Box of 5's) | Rx | Farbe Firma Pvt. LtdIndia | Genzen Pharmaceutical TradingImporter: AMB HK Enterprises Inc. | DRP-13797-02 | May 2, 2028 | |
GlotrekTranexamic Acid | 100 mg/mL (500 mg/5 mL) Solution for Injection (IV)Type I Clear Colorless Glass Ampoule x 5 mL (Net Content) in Plastic Tray (Box of 5's) | Rx | UNIJULES LIFE SCIENCES LIMITEDIndia | AGLOBAL CARE, INC. | DRP-8687 | May 20, 2029 | |
HaemonavTranexamic Acid | 100 mg/mL (500 mg/5 mL) Solution for Injection (IV)Type I Clear Colorless Glass Ampoule x 5 mL (Net Content) in Plastic Tray (Box of 5's) | Rx | Unijules Life Sciences LimitedIndia | JN Carlo Pharmaceuticals DistributorImporter: Aglobal Care, Inc. | DRP-8687-07 | May 20, 2029 | |
HaemorexTranexamic Acid | 500 mg CapsuleAlu/PVC Blister Pack x 10's (Box of 100's) | Rx | New Myrex Laboratories, Inc.Philippines | — | DRP-2328 | Mar 4, 2031 | |
HemanexTranexamic Acid | 100 mg/mL (500 mg/mL) Solution fo Injection (IM/IV)USP Type I Clear Glass Ampoule in a PVC Tray x 5 mL (Box of 5's) | Rx | Amherst Parenterals, Inc.Philippines | Trader: Unilab, Inc. | DR-XY43305 | Mar 13, 2029 | |
HemanexTranexamic Acid | 500 mg CapsuleAluminum Blister Pack x 10's (Box of 100's) | Rx | Amherst Laboratories, Inc.Philippines | Trader: UNILAB, Inc | DRP-11169 | Feb 9, 2027 | |
HemanexTranexamic Acid | 500 mg CapsuleBlister Pack x 10's Box of 100's | Rx | Amherst Laboratories, Inc.Philippines | UNILAB, Inc. | DRP-2847-02 | May 24, 2027 | |
HemarifeTranexamic Acid | 100 mg/mL Solution For Injection (IV)Clear glass ampoule x 5 mL in plastic tray x 10's | Rx | Reyoung Pharmaceutical Co., Ltd.China | Dynasty Pharmaceuticals | DRP-14021 | Jun 6, 2028 | |
HematranTranexamic Acid | 100 mg/mL Solution for Injection (IV)Type I clear glass ampoule x 5 mL (Box of 5’s & 10’s) | Rx | Scott-Edil Pharmacia LimitedIndia | Epione Lifecare Inc.Importer: Despina Pharma Inc. | DRP-14765-01 | Dec 29, 2028 | |
HemitanTranexamic acid | 500 mg Film Coated TabletAlu/PVC Blister Pack x 10's (Box of 30's) | Rx | Exemed PharmaceuticalsIndia | AMB HK Enterprises Inc. | DRP-17134 | Oct 10, 2031 | |
HemobasTranexamic Acid | 100 mg/mL (500 mg/5 mL) Solution for Injection (IM/IV)5 mL USP Type I Clear, Colorless Glass Ampoule (Box of 10's) | Rx | Friends Pharma (Pvt.) Ltd.Pakistan | RAQUEL-ABBAS PHARMACEUTICALS & GENERAL MERCHANDISE | DRP-9087 | Feb 19, 2029 | |
HemocareTranexamic Acid | 100 mg/mL (500 mg/5 mL) Solution for Injection (IV)Type I Clear Colorless Glass Ampoule x 5 mL (Net Content) in Plastic Tray (Box of 5’s) | Rx | Unijules Life Sciences LimitedIndia | Euro-Care Products PhilippinesImporter: Aglobal Care, Inc. | DRP-8687-04 | May 20, 2029 | |
HemocareTranexamic Acid | 500 mg/5 mL (100 mg/mL) Solution for Injection (IM/IV)5 mL clear colorless glass ampoule (Box of 5's) | Rx | Furen Pharmaceutical Group Co., Ltd.China | Asianmeds, Inc.Importer: Euro-Care Products Philippines | DRP-15310-03 | Jun 18, 2029 | |
HemocareTranexamic Acid | 500mg/5mL Solution for Injection | Rx | Alina Combine Pharmaceutical (Pvt.) Ltd. | — | DRP-3418-05 | Dec 6, 2026 | |
HemoclotTranexamic Acid | 250 mg CapsuleBlister Pack x 10's (Box of 100's) | Rx | Lloyd Laboratories, Inc.Bulacan | Solvang Pharmaceuticals, Inc.Trader: Eadriex Pharmaceuticals, Phils., Inc. | DRP-4058-01 | Oct 5, 2036 | |
HemoclotTranexamic Acid | 500 mg CapsuleAlu/Clear PVDC Blister Pack of 10's Box of 100's | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Solvang Pharmaceuticals, Inc. | DRP-10014 | Jul 19, 2027 | |
HemodenTranexamic Acid | 100 mg/mL (500 mg/5 mL) Solution for Injection (IM/IV)USP Type I clear glass ampoule x 5 mL in PVC plastic tray (Box of 5's) | Rx | Farbe FirmaIndia | Cyden Medicale Trading Inc.Importer: AMB HK Enteprises Inc. | DRP-13797-01 | May 2, 2028 | |
HemofarTranexamic Acid | 500 mg Film-Coated TabletAlu/Alu Blister Pack of 10's (Box of 100's) | Rx | Healer's Lab. Unit IIIndia | Pharmakon Biotec Inc. | DRP-5424 | Aug 5, 2029 | |
HemofixTranexamic Acid | 100 mg / mL (500 mg / 5 mL) Solution for Injection (IV)USP Type I clear glass ampoule x 5 mL (net content) in a plastic tray (Box of 5's) | Rx | Skymap Healthcare Pvt. Ltd.India | GA2 Pharmaceutical IncImporter: Medinova Pharmaceutical Inc. | DRP-15874-02 | Sep 25, 2029 | |
HemoflazTranexamic Acid | 100 mg/mL Solution for Injection (IV)Type I clear glass ampoule x 5 mL (Box of 5's and 10's) ` | Rx | Scott-Edil Pharmacia LimitedIndia | Despina Pharma Inc. | DRP-14765 | Dec 29, 2028 | |
HemosaveTranexamic Acid | 500 mg / 5 mL (100 mg / mL) Solution for Injection (IV)5 mL USP Type I Clear Ampoule (Box of 5's and 10's) | Rx | Maxitech Pharma (Pvt.) Ltd.Pakistan | Savelink Pharma and Trading Co.Importer: Accesspoint International Trading Inc. | DRP-15221-02 | Jun 18, 2029 | |
HemosolvTranexamic Acid | 500 mg CapsuleAlu/Clear PVDC Blister Pack of 10's (Box of 100's) | Rx | Lloyd Laboratories, Inc.Philippines | Dr. Zen's Research, Inc.Trader: Solvang Pharmaceuticals, Inc. | DRP-10014-01 | Jul 19, 2027 | |
HemostanTranexamic acid | 100 mg/mL (250 mg/2.5 mL) Solution for Injection (IM/IV)Clear Colorless Glass Ampoule x 2.5 mL (Box of 5's) | Rx | Amherst Parenterals, Inc.Philippines | Trader: UNILAB, INC. | DR-4759 | Sep 16, 2027 | |
HEMOSTANTranexamic acid | 100 mg/mL (500 mg/5 mL) Solution for Injection (IM/IV)Clear Colorless Glass Ampoule x 5 mL Box of 5's | Rx | Amherst Parenterals, Inc.Philippines | Trader: UNILAB, INC. | DRP-8449 | Sep 16, 2027 | |
HemostanTranexamic Acid | 250 mg CapsuleAlu/Clear PVC Blister Pack x 10's (Box of 100's) | Rx | Amherst Laboratories, Inc.Philippines | Trader: UNILAB, Inc. | DR‐5167 | Oct 24, 2027 | |
HemostanTranexamic Acid | 500 mg CapsuleBlister Pack x 10's (Box of 100's) | Rx | Amherst Laboratories, Inc.Philippines | Trader: UNILAB, Inc. | DRP-2847 | May 24, 2027 | |
HemostapTranexamic Acid | 250 mg CapsuleAlu/PVC Blister Pack x 10's (Box of 30's and 100's) | Rx | Azarias Pharmaceutical Laboratories Inc.Philippines | — | DRP-4271 | Feb 26, 2028 | |
HemostapTranexamic Acid | 500 mg CapsulePVC Blister Pack x 10's (Box of 30's and 100's) | Rx | Azarias Pharmaceutical Laboratories Inc.Philippines | — | DRP-4204 | Feb 8, 2028 | |
HemostarTranexamic Acid | 500 mg CapsulePVC Blister Pack x 10's (Box of 100's) | Rx | Azarias Pharmaceutical Laboratories Inc.Philippines | Starpharm, Inc. | DRP-4204-04 | Feb 8, 2028 | |
HemostatTranexamic Acid | 500mg CapsuleAlu/Clear PVC Blister Pack x 10's (Box of 20's) | Rx | Aristopharma Ltd.Bangladesh | Sahar International Trading, Inc. | DR-XY41545 | Jan 10, 2028 | |
HemostivaTranexamic Acid | 100mg/mL Solution for Injection (IV)Type I Glass Ampoule x 5 mL in PVC Tray (Box of 5’s and 10's) | Rx | Reyoung Pharmaceutical Co., Ltd..China | Philrx Pharma Inc. | DRP-18919 | Sep 30, 2031 | |
HemotranTranexamic Acid | 500 mg CapsuleBlister Pack x 10's (Box of 100's) | Rx | LLOYD LABORATORIES, INC.Philippines | ALTOMED PHARMACEUTICALS, INC.Trader: FORAMEN PRODUCTS CORPORATION | DRP-718-03 | Sep 22, 2031 | |
HemotraxTranexamic Acid | 100 mg/mL (500 mg/5 mL) Solution for Injection (IV)USP Type I clear glass ampoule x 5 mL (net content) in a plastic tray (Box of 5's) | Rx | Skymap Healthcare Pvt. Ltd.India | GA2 Pharmaceutical IncImporter: Medinova Pharmaceutical Inc. | DRP-15874-01 | Sep 25, 2029 | |
HemotrexTranexamic Acid | 100 mg/mL (500 mg/5 mL) Solution for Injection (IV)Type I Clear Colorless Glass Ampoule x 5 mL (as net content) in Plastic Tray (Box of 5’s) | Rx | UNIJULES LIFE SCIENCES LIMITEDIndia | NUTRAMEDICA INCImporter: AGLOBAL CARE, INC. | DRP-8687-02 | May 20, 2029 | |
HemotrexTranexamic Acid | 500 mg CapsuleBlister Pack x 10's (Box of 100's) | Rx | Lloyd Laboratories, Inc.Philippines | Nutramedica Inc.Trader: Foramen Products Corporation | DRP-718 | Oct 2, 2031 | |
HemoveeTranexamic Acid | 100 mg/mL (500mg/5mL) Solution for Injection (I.M./I.V.)5 mL USP Type 1 Low Borosilicate Glass Ampoule (Box of 10's) | Rx | Reyoung Pharmaceutical Co., Ltd.China | Euro-Care Products Philippines. | DRP-15351 | Jul 3, 2029 | |
HemoxaneTranexamic Acid | 100 mg/mL Solution for injection (IV)USP Type I Clear Glass Ampoule x 5 mL (Box of 5's) | Rx | Mercury Laboratories Ltd.India | Phil Pharmawealth, Inc. | DR-XY44554 | May 14, 2027 | |
HemoxaneTranexamic Acid | 500 mg TabletAlu/PVC Blister Pack x 10's (Box of 50's) | Rx | Mercury Laboratories Ltd.India | Phil Pharmawealth Inc. | DR-XY38149 | Jun 5, 2030 | |
HemoxidTranexamic Acid | 500 mg CapsuleBlister Pack x 10's (Box of 100's) | Rx | Lloyd Laboratories, Inc.Philippines | TGP Pharma Inc.Trader: Foramen Products Corporation | DRP-718-01 | Sep 1, 2031 | |
HemoxinTranexamic Acid | 500 mg CapsuleAlu/Clear PVC Blister pack x 10's (Box of 100's) | Rx | Drugmaker's Laboratories, Inc.Philippines | — | DRP-5833 | Mar 15, 2030 | |
KEXAMICTranexamic Acid | 100 mg/mL (500 mg/5 mL) Solution for Injection (IV)Type I Clear Colorless Glass Ampoule x 5 mL (as net content) in Plastic Tray (Box of 5’s) | Rx | UNIJULES LIFE SCIENCES LIMITEDIndia | PHARMA KING DISTRIBUTORImporter: AGLOBAL CARE, INC. | DRP-8687-03 | May 20, 2029 | |
KhrizemicTranexamic Acid | 100 mg/mL (500 mg/5 mL) Solution for Injection (I.V.)5 mL (net content) USP Type I clear and colorless glass ampoule x 5 ampoules in a plastic tray (box of 25 ampoules) | Rx | Skymap Healthcare Pvt. Ltd.India | Khriz Pharma Trading, Inc. | DR-XY49092 | May 24, 2029 | |
KontranexTranexamic Acid | 500 mg CapsuleAlu/Clear PVC Blister Pack x 10's (Box of 100's) | Rx | Azarias Pharmaceutical Laboratories Inc.Philippines | Konzept Convenience and Drug Store Corp. | DRP-4204-03 | Feb 8, 2028 | |
MixtranzTranexamic Acid | 100 mg/mL (500 mg/ 5 mL) Solution for Intravenous (I.V.) InjectionUSP Type I clear glass ampoule with tray x 5 mL (Box of 10’s) | Rx | Makcur Laboratories LimitedIndia | AGB Pharmaceutical Trading and Consultancy CorporationImporter: Diafarm Inc. | DRP-11560-02 | Mar 30, 2027 | |
NexavellTranexamic acid | 100 mg/mL (500 mg/5 mL) Solution for Injection (IM/IV)Type I Clear Glass Ampoule x 5 mL (Box of 5's) | Rx | PT. Novell Pharmaceutical LaboratoriesIndonesia | Prosweal Healthcare Inc. | DR-XY43251 | Dec 10, 2028 | |
NexzatranTranexamic Acid | 100 mg/mL (500 mg/5 mL) Solution for Intravenous (I.V.) InjectionUSP Type I clear glass ampoule with tray x 5 mL (Box of 10’s) | Rx | Makcur Laboratories LimitedIndia | Ambicare Pharmaceuticals Inc.Importer: Diafarm Inc. | DRP-11560-03 | Mar 30, 2037 | |
NoneTranexamic Acid | 100 mg /mL (500 mg / 5 mL) Solution for Injection (I.V.)USP Type I clear colourless glass ampoule x 5 mL (Box of 5’s) | Rx | East African (India) OverseasIndia | Reta DrugImporter: Ambica International Corporation | DRP-13005-02 | Nov 16, 2027 | |
NoneTranexamic Acid | 100 mg/mL (500 mg/5 mL) Solution for Injection (IM/IV)Clear glass ampoule x 5 mL in Alu/PVC blister (Box of 4’s) | Rx | Mankind Pharma Limited (Unit-I)India | Reta DrugImporter: Ambica International Corporation | DRP-14087-01 | Jun 20, 2028 | |
NoneTranexamic acid | 100 mg/mL (500 mg/5 mL) Solution for Injection (IM/IV)Clear Colorless Glass Ampoule x 5 mL Box of 5's | Rx | Amherst Parenterals, Inc.Philippines | RITEMED PHILS., INC.Trader: UNILAB, INC. | DRP-8449-01 | Sep 16, 2027 | |
NoneTranexamic Acid | 100 mg/mL (500 mg/5 mL) Solution for Intravenous InjectionUSP Type I Flint Glass Ampoule x 5 mL (Box of 5's) | Rx | Gufic Biosciences LimitedIndia | Scheeling, Inc.Importer: Ambica International Corporation | DRP-5172-02 | Feb 13, 2029 | |
NoneTranexamic Acid | 500 mg CapsuleAlu/Clear PVC Blister Pack x 10's (Box of 100's) | Rx | Drugmaker's Laboratories IncPhilippines | TGP Pharma Inc. | DRP-5833-01 | Mar 15, 2030 | |
PantrexTranexamic Acid | 100 mg/mL (500 mg/5 mL) Solution for Injection (IV)USP Type I Glass Ampoule x 5 mL (Box of 10's) | Rx | Ying Yuan Chemical Pharmaceutical Co., Ltd.Taiwan | Pan-Ject Pharmaceuticals Corp. | DRP-626 | Mar 21, 2030 | |
Pause 500Tranexamic Acid. | 500 mg Film-Coated TabletAlu/Alu Blister Pack x 10 Tablets (Box of 30's) | Rx | Emcure Pharmaceuticals Ltd.India | Emcure Pharma Philippines Inc. | DR-XY49072 | May 7, 2029 | |
PillxamicTranexamic Acid | 100 mg/mL (500 mg/5 mL) Solution for Injection (I.V.)USP Type I clear colourless glass ampoule x 5 mL (Box of 5’s) | Rx | East African (India) OverseasIndia | AGB Pharmaceutical Trading and Consultancy CorporationImporter: Ambica International Corporation | DRP-13005-03 | Nov 16, 2027 | |
PremtexaTranexamic Acid | 100 mg / mL (500 mg/5 mL) Solution for Injection (I.V.)USP Type I clear colourless glass ampoule x 5 mL (Box of 5’s) | Rx | East African (India) OverseasIndia | Premier Pharmaceuticals Marketing Corp.Importer: Ambica International Corporation | DRP-13005-04 | Nov 16, 2027 | |
RanesanTranexamic Acid | 100 mg / mL (500 mg / 5 mL) Solution for Injection (IV)Type I Clear Colorless Glass Ampoule x 5 mL (Net Content) in Plastic Tray (Box of 5's) | Rx | Unijules Life Sciences LimitedIndia | Sannovex Pharmaceutical DistributorImporter: Aglobal Care, Inc. | DRP-8687-05 | May 20, 2029 | |
RanexTranexamic Acid | 100 mg/mL Solution for Injection (IV)USP Type I clear glass ampoule x 5 mL (Box of 5 ampoules in plastic tray) | Rx | Steril-Gene Life Sciences (P) Ltd.India | Aglobal Care, Inc. | DRP-11981 | May 25, 2027 | |
RanexidTranexamic Acid | 100mg/mL Solution for Injection (IV)Clear Glass Ampoule x 5mL (Box of 10's) | Rx | Yung Shin Pharm. Ind. Co., Ltd- Taichung Youth FactoryChina | Dynasty PharmaceuticalsImporter: Yung Shin (Philippines), Inc. | DRP-1043-01 | Nov 13, 2027 | |
RanexstarTranexamic Acid | 100 mg/mL (500 mg/5mL) Solution for Injection (IV)USP Type I clear glass ampoule x 5 mL (net content) in a plastic tray (Box of 5's) | Rx | Skymap Healthcare Pvt. Ltd.India | Twostar Pharmaceutical TradingImporter: Medinova Pharmaceutical Inc. | DRP-15874-03 | Sep 25, 2029 | |
RaxamiTranexamic Acid | 100 mg/Ml Solution For InjectionAmber glass ampoule with blue band x 5 mL (Box of 5 ampoules in a tray) | Rx | SANJAR PHARMA LLPIndia | Aglobal Care, Inc.Trader: Antila Lifesciences Pvt. Ltd. | DRP-14194 | Jul 17, 2028 | |
RexamicTranexamic Acid | 100 mg/mL (500 mg/5 mL) Solution for Injection (IV)Type I clear transparent ampoule in a carton x 5 mL (box of 5’s) | Rx | Hiral Labs LimitedIndia | Bellus Life Solutions, Inc. | DRP-18052 | Apr 30, 2031 | |
SitixamicTranexamic Acid | 500 mg/5 mL Solution for Injection (I.V.)Low Borosilicate Glass Ampoules in a Plastic Tray x 5 mL x 10's (Box of 10's) | Rx | Tianjin Kingyork Group Hubei Tianyao Pharmaceutical Co., Ltd.China | Sahar International Trading Inc.Trader: ZLF Pharmaceutical Limited | DR-XY49124 | Jul 5, 2029 | |
SuprehemTranexamic Acid | 500 mg CapsuleAlu/PVC Blister Pack x 10’s Box of 100’s | Rx | Flamingo Pharmaceuticals Ltd.India | Hexagon Pharmaceuticals | DR-XY41289 | Oct 2, 2027 | |
TafixylTranexamic Acid | 500 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 20's) | Rx | Labiana Pharmaceuticals, S.L.USpain | Qualicare Pharma, Inc.Trader: Pharma Bavaria International GmbH | DR-XY48117 | Jun 17, 2027 | |
TanegoTranexamic Acid | 100 mg/mL (500 mg/5 mL) Solution for Injection (IV)Type I Clear Glass Ampoule x 5 mL in White Hips Plastic Tray (Box of 10's) | Rx | Makcur Laboratories LimitedIndia | Importer: Afree Pharmaceutical Distribution Corp. | DRP-12666 | Sep 22, 2027 | |
TarnaxTranexamic Acid | 100 mg/mL Solution for Injection (I.M./I.V.)5 mL USP Type I clear glass tray (Box of 5's) | Rx | Swiss Parenterals Ltd. (Block-B)India | Despina Pharma Inc | DRP-15630 | Aug 13, 2029 | |
TarnexTranexamic Acid | 500 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Medhaus Pharma, Inc. | DR-XY35552 | May 30, 2029 | |
TazojorTranexamic Acid | 100 mg/mL (500mg/5 mL) Solution for Injection (I.V)USP Type I clear colourless glass ampoule x 5 mL (Box of 5's) | Rx | East African (India) OverseasIndia | Ambica International Corporation | DRP-13006 | Nov 16, 2027 | |
TexakindTranexamic Acid | 100 mg/mL (500 mg/5 mL) Solution for Injection (IM/IV)Clear transparent Glass Ampoule with colored collar ring packed in an Alu/PVC Blister x 5 mL | Rx | Mankind Pharma Limited (Unit-I)India | Ambica International Corporation | DRP-14087 | Jun 20, 2028 | |
TracidTranexamic acid | 100 mg/mL (500 mg/5 mL) Solution for Injection (IV)USP Type I Clear glass ampoule x 5 mL (Box of 5's) | Rx | Swiss Parenterals Ltd. (Block-B)India | Applied Pharmaceutical Distribution Inc. | DRP-15035 | Mar 22, 2029 | |
TrajexTranexamic Acid | 100 mg/mL Solution For Injection (IM/IV)Type I Clear Glass vial Ampoule x 2.5 mL and 5 mL (Box of 5's and 10's) | Rx | Jiangsu Ruinian Qianjin Pharmaceutical Co., Ltd.China | Raquel Abbas Pharma Inc. | DRP-18950 | Oct 6, 2031 | |
TraliteTranexamic Acid | 500 mg Film-Coated TabletAlu/PVC blister pack x 10’s (Box of 30’s) | Rx | Globela Pharma Private LimitedIndia | Fspc Pharmaceuticals Inc.Importer: Amb Hk Enterprises Inc. | DRP-12770-02 | Oct 6, 2027 | |
TramacidTranexamic Acid | 500 mg CapsulePVC Blister Pack x 10's (Box of 100's) | Rx | Azarias Pharmaceutical Laboratories Inc.Philippines | St. Raphael Archangel Pharmaceutical Product Distribution | DRP-4204-01 | Feb 8, 2028 | |
TramedTranexamic Acid | 500 mg Film-Coated TabletAlu-Alu Blister Pack x 10's (Box of 30's; Box of 100's) | Rx | Acme Formulation Pvt. Ltd.India | Medinova Pharmaceutical Inc. | DRP-10306 | Sep 9, 2031 | |
Tramic-500Tranexamic Acid | 500 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's) | Rx | West Coast Pharmaceutical Works Ltd.India | Ambica International Corporation | DRP-6193 | Jun 23, 2030 | |
TranceTranexamic Acid | 100 mg/mL (500 mg/5 mL) Solution for injection (IV)USP TYpe I Clear glass Ampoule x 5 mL (Box of 5's) | Rx | Celon Laboratories Private LimitedIndia | Meedpharma Medical Supplies & Equipment DistributorImporter: I.E Medica, Inc. | DRP-4153 | Dec 18, 2030 | |
Trancid-500Tranexamic Acid | 500 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 30's) | Rx | Fredun Pharmaceuticals LimitedIndia | AMB HK Enterprises Inc. | DRP-18217 | Jun 2, 2031 | |
Trane-WestTranexamic Acid | 100 mg/mL (500 mg/5 mL) Solution for Intravenous InjectionUSP Type I Flint Glass Ampoule x 5 mL (Box of 5's) | Rx | Gufic Biosciences LimitedIndia | Central West Medicale Inc.Importer: Ambica International Corporation | DRP-5172-05 | Feb 13, 2029 | |
Tranellen-PE100Tranexamic Acid | 100mg/mL Solution for Injection (IM/IV)5 mL and 2.5 mL USP Type I amber glass ampoule (Box of 5’s and 10’s) | Rx | Penam Biosciences Pvt. Ltd.India | Ollen Pharma Trading Inc. | DRP-18594 | Aug 4, 2031 | |
TranesalvTranexamic Acid | 500mg/5mL Solution for Injection | Rx | Alina Combine Pharmaceutical (Pvt.) Ltd. | — | DRP-3418-02 | Dec 6, 2026 | |
TranesaphTranexamic Acid | 100mg/mL Solution For Injection (IV)USP Type I Flint glass ampoule x 5 mL (Box of 10 ampoules in PVC tray; Box of 5 ampoules in PVC tray); USP Type I Flint glass ampoule x 2.5 mL (Box of 10 ampoules in PVC tray; Box of 5 ampoules in PVC tray) | Rx | Kilitch Drugs (India) Ltd.India | Nelpa Lifesciences, Inc.Trader: Sapphire Lifescience Pvt. Ltd. | DRP-11329 | Mar 3, 2027 | |
TranesaveTranexamic Acid | 100 mg / mL (500 mg /5 mL) Solution for Injection (I.V.)USP Type I clear colourless glass ampoule x 5 mL (Box of 5’s) | Rx | East African (India) OverseasIndia | Curasave Ve PharmaImporter: Ambica International Corporation | DRP-13005-01 | Nov 16, 2027 | |
TranexTranexamic Acid | 100 mg/mL (500 mg/5 mL) Solution for Injection (IV)Type I Clear Colorless Glass Ampoule x 5 mL (Net Content) in Plastic Tray (Box of 5's) | Rx | Unijules Life Sciences LimitedIndia | Medirich Pharma Distribution Corp.Importer: Aglobal Care, Inc. | DRP-8687-06 | May 20, 2029 | |
Tranexa IVTranexamic Acid | 100 mg/mL Solution for Injection (IV)USP Type I amber Glass ampoule x 5mL (Box of 10's) | Rx | Reyoung Pharmaceutical Co., Ltd.China | Pharmakon Biotec Inc. | DRP-11331 | Mar 3, 2027 | |
TranexagenTranexamic Acid | 250 mg CapsuleAlu/Clear PVC Blister Pack x 10's (Box of 100's) | Rx | Azarias Pharmaceutical Laboratories Inc.Philippines | Eba Generisch Trading Inc. | DRP-4271-01 | Feb 26, 2028 | |
TranexamTranexamic Acid | 100 mg / mL (500 mg / 5 mL) Solution for Injection (IV)Type I Colorless Glass Ampoule x 5 mL (Box of 10's) | Rx | Union Korea Pharm Co., Ltd.Republic of Korea | Central West Medicale Inc.Importer: H&B Pharma International Inc. | DRP-10924-01 | Dec 17, 2026 | |
TranexaminTranexamic Acid | 100 mg / mL (500 mg/ 5 mL) Solution for Injection (IM/IV)USP Type I Clear and Colorless Glass Ampoule x 5 mL (Box of 10's) | Rx | Daihan Pharm. Co., Ltd.Republic of Korea | Largen Med Inc | DRP-15703 | Mar 5, 2028 | |
TranexaminTranexamic Acid | 100 mg/ mL (500 mg/ 5 mL) Solution for Injection (IM/IV)USP Type I Clear and Colorless Glass Ampoule x 5 mL Box of 10's | Rx | Daihan Pharm. Co., Ltd.Republic of Korea | Largen Med Inc. | DR-XY46273 | Mar 5, 2028 | |
TranexaprimeTranexamic Acid | 100 mg/mL (500 mg/5 mL) Solution for Intravenous InjectionUSP Type I Flint Glass Ampoule x 5 mL (Box of 5's) | Rx | Gufic Biosciences LimitedIndia | AGB Pharmaceutical Trading and Consultancy CorporationImporter: Ambica International Corporation | DRP-5172-04 | Feb 13, 2029 | |
TranexareTranexamic Acid | 500 mg/5 mL (100 mg/mL) Solution for Injection (IV)5 mL USP Type I Clear Glass Ampoule (Box of 5's) | Rx | Maxitech Pharma (Pvt.) Ltd.Pakistan | Neo Care Philippines, Inc.Importer: Accesspoint International Trading Inc. | DRP-15221-01 | Jun 18, 2029 | |
TranexbestTranexamic Acid | 500 mg/5 mL (100 mg/mL) Solution for Injection (IM/IV)5 mL clear colorless glass ampoule (Box of 5's) | Rx | Furen Pharmaceutical Group Co., Ltd.China | Best ClearImporter: Euro-Care Products Philippines | DRP-15310-01 | Jun 18, 2029 | |
TranexellTranexamic Acid | 100 mg/mL (500 mg/5 mL) Solution for Intravenous InjectionUSP Type I Flint Glass Ampoule x 5 mL (Box of 5's) | Rx | Gufic Biosciences LimitedIndia | Tamiga Pharmaceuticals SupplyImporter: Ambica International Corporation | DRP-5172-06 | Feb 13, 2029 | |
TranexfreeTranexamic Acid | 100mg/mL (500mg/5mL) Solution for Injection (IV)Type I Clear Glass Ampoule x 5 mL in White Hips Plastic tray (Box of 10's) | Rx | Makcur Laboratories LimitedIndia | Bliss Pharma Distribution And Consultancy Corp.Importer: Afree Pharmaceutical Distribution Corp. | DRP-12666-01 | Sep 22, 2027 | |
TranexidTranexamic Acid | 500 mg/5 mL Solution for Injection (I.M. / I.V.)USP Type I Clear Glass Ampoule x 5mL (Box of 5's) | Rx | Alina Combine Pharmaceutical (Pvt.) Ltd.Pakistan | Seahorse Industries, Inc.Importer: West Wing Pharma Sales Inc. | DRP-3418-04 | Dec 6, 2026 | |
TranexmedTranexamic Acid | 500 mg/5 mL (100 mg/mL) Solution for Injection (IM/IV)5 mL clear colorless glass ampoule (Box of 5's) | Rx | Furen Pharmaceutical Group Co., Ltd.China | Blue Medceuticals Marketing Corp.Importer: Euro-Care Products Philippines | DRP-15310-02 | Jun 18, 2029 | |
TranexsaphTranexamic Acid | 500 mg CapsuleAlu/Clear PVC Blister Pack x 10's (Box of 100's) | Rx | Sapphire Lifesciences Pvt. Ltd.India | Nelpa Lifesciences, Inc. | DRP-13371 | Feb 8, 2028 | |
TRANEXSETHTranexamic Acid | Capsule 500 mgAlu/Clear PVC Blister Pack x 10’s (Box of 100's) | Rx | Genom Biotech Pvt. Ltd.India | 999-SETH PHARMACEUTICAL INC.Importer: Nelpa Lifesciences, Inc. | DRP-14574-01 | May 19, 2030 | |
TranextTranexamic Acid | 500 mg CapsuleAlu/Clear PVC Blister Pack x 10's (Box of 100's) | Rx | Azarias Pharmaceutical Laboratories Inc.Philippines | — | DRP-4534 | Jul 23, 2028 | |
TranezTranexamic Acid | 100 mg/mL (500 mg/5 mL) Solution for Injection (I.M./I.V.)USP Type I Clear Glass Ampoule x 5 mL (Box of 10 ampoules x 5mL in plastic tray) | Rx | Makcur Laboratories LimitedIndia | Seapharma International, IncTrader: Yeluri Formulations Pvt. Ltd. | DRP-13959 | Sep 24, 2029 | |
TranhilTranexamic Acid. | 100 mg/mL (500 mg/5 mL) Solution for Injection (I.M./I.V.)5 mL Type I clear glass ampoule (Box of 10's) | Rx | Makcur Laboratories Limited.India | Hillcross Prime, Inc. | DRP-12009 | Sep 24, 2029 | |
TranickoTranexamic Acid | 100 mg/mL Solution for Injection (IM/IV)USP Type I clear glass ampoule x 5mL in plastic tray x 5's (Box of 5's) | Rx | Pharmax India Private LimitedIndia | Wellchem Pharmaceutical Products | DRP-16705 | Jun 24, 2030 | |
TranijectTranexamic Acid | 100 mg/mL (500 mg/5 mL) Solution for Intravenous InjectionUSP Type I Flint Glass Ampoule x 5 mL (Box of 5's) | Rx | Gufic Biosciences LimitedIndia | Meedpharma Medical Supplies & Equipment DistributorImporter: Ambica International Corporation | DRP-5172-03 | Feb 20, 2029 | |
TranixTranexamic Acid | 100 mg/mL (500 mg/5 mL)Solution for Injection (IV)USP Type I Clear Glass Ampoule x 5 mL Box of 5's | Rx | Celon Laboratories Private LimitedIndia | Medethix, Inc.Importer: I.E MEDICA INC. | DRP-4153-02 | Sep 29, 2031 | |
TranmedTranexamic Acid | 100mg/mL (500mg/5mL) Solution For Injection (IM/IV)5mL Type I clear ampoule (Box of 5's) | Rx | Medchem International LimitedIndia | Pharma-Surrey International, Inc. | DR-XY40235 | Nov 17, 2026Past listed date | |
TranovaTranexamic acid. | 500 mg CapsuleAlu/PVC Blister Pack x 10's (Box of 10's & 100's) | Rx | Saga Lifesciences LimitedIndia | Medinova Pharmaceutical Inc. | DRP-15289 | Jun 10, 2029 | |
TranquafixTranexamic Acid | 500 mg CapsuleAlu / PVC Blister Pack x 10's (Box of 10's & 100's) | Rx | Saga Lifesciences LimitedIndia | GA2 Pharmaceutical IncImporter: Medinova Pharmaceutical Inc. | DRP-15289-01 | Jun 10, 2029 | |
TransanTranexamic Acid | 100 mg/mL Solution For Injection (IV)5 mL USP Type-I Flint Glass Ampoule In A Plastic Tray (Box of 5's) | Rx | Gufic Biosciences Ltd.India | SRS Pharmaceuticals Phils Inc. | DR-XY46073 | Oct 6, 2027 | |
Transtat 500Tranexamic Acid | 500 mg Film-Coated TabletAlu/Clear PVC/PVdC Blister Pack x 10's (Box of 60's); Alu/Clear PVC/PVdC Blister Pack x 4's (Physician's Sample) | Rx | Kusum Healthcare Pvt. Ltd.India | Kusum Healthcare Private Limited Branch Office | DR-XY46215 | Jan 26, 2030 | |
TrantranTranexamic Acid | 100 mg/mL (500 mg/5 mL) Solution for Injection (I.V.)5mL Clear Glass Ampoule in PVC Tray (Box of 5's) | Rx | Pharmax India Private LimitedIndia | Ambica International Corporation.Importer: Ambica International CorporationTrader: Rainbow Life Sciences Pvt. Ltd. | DRP-13016 | Nov 17, 2027 | |
TranzTranexamic Acid | 500 mg Film-Coated TabletAlu/Alu Blister Pack of 10's (Box of 100's) | Rx | Healer's Lab. Unit IIIndia | One Technodrug Life Sciences Inc.Importer: Pharmakon Biotec Inc. | DRP-5424-02 | Aug 5, 2029 | |
TranzilTranexamic Acid | 500 mg Film-Coated TabletAlu-Alu Blister Pack x 10’s (Box of 100’s) | Rx | XL Laboratories Pvt. Ltd.India | Ambica International Corporation | DRP-3208 | Aug 25, 2031 | |
TraxanTranexamic Acid | 100 mg/mL (500 mg/5 mL) Solution for Intravenous InjectionUSP Type I Flint Glass Ampoule x 5 mL (Box of 5's) | Rx | Gufic Biosciences LimitedIndia | Multicare Pharmaceuticals Phils. Inc.Importer: Ambica International Corporation | DRP-5172-01 | Feb 13, 2029 | |
TraxanTranexamic Acid | 500 mg CapsuleAlu/Clear PVC Blister Pack x 10's (Box of 100's) | Rx | Lloyd Laboratories, Inc.Bulacan | Multicare Pharmaceuticals Philippines, Inc.Trader: Eadriex Pharmaceuticals, Phils., Inc. | DRP-721-03 | Oct 5, 2031 | |
TraxozolTranexamic Acid | 100 mg / mL mg/mL Solution for Injection (IV)USP Type 1 Amber Glass Ampoule x 5 mL (Box of 5's in a PVC tray) | Rx | Kamla Lifesciences Ltd.India | Ambica International CorporationTrader: Omnicals Pharma Private Limited | DRP-18472 | Jul 23, 2031 | |
TrazuperTranexamic Acid | 100 mg/mL (500mg/5 mL) Solution for Injection (I.V.)USP Type I clear colourless glass ampoule x 5 mL (Box of 5's) | Rx | East African (India) OverseasIndia | Ambica International Corporation | DRP-13005 | Nov 16, 2027 | |
TrenaxidTranexamic Acid | 100 mg / ml Solution for Injection (IV)Type I clear glass ampoule x 5 ml (Box of 5’s and 10's) | Rx | Scott-Edil Pharmacia LimitedIndia | Epione Lifecare Inc.Importer: Despina Pharma Inc. | DRP-14765-02 | Dec 29, 2028 | |
TrenaxinTranexamic Acid | 100mg/mL Solution for Injection (IV)Clear Glass Ampoule x 5mL Box of 10's | Rx | Yung Shin Pharm., Ind. Co., Ltd.- Taichung Youth FactoryR.O.C | Yung Shin (Philippines), Inc. | DRP-1043 | Nov 13, 2027 | |
TrenaxinTranexamic Acid | 250mg CapsuleAlu/PVC Blister Pack x 10's Box of 100's | Rx | Y.S.P. Industries (M) Sdn. Bhd.Malaysia | Yung Shin (Philippines), Inc. | DR-XY35553 | Mar 5, 2031 | |
TrenaxinTranexamic acid | 500 mg/5 mL (100 mg/mL) Solution for Intravenous5 mL-net content Type I clear glass ampoule (Box of 10's). | Rx | Y.S.P. Industries (M) Sdn. Bhd.Malaysia | Yung Shin (Philippines), Inc. | DRP-15536 | Jul 31, 2029 | |
TrenzamicTranexamic Acid | 100 mg/mL (500 mg/5 mL) Solution for Intravenous (I.V.) InjectionUSP Type I Clear Glass Ampoule with Tray x 5 mL (Box of 10’s) | Rx | Makcur Laboratories LimitedIndia | Diafarm Inc. | DRP-11560 | Mar 30, 2032 | |
TrexablissTranexamic Acid | 100 mg/mL (500 mg/5 mL) Solution for Injection (IV)Type I Clear Glass Ampoule x 5 mL in White Hips Plastic Tray (Box of 10's) | Rx | Makcur Laboratories LimitedIndia | Bliss Pharma Distribution and Consultancy Corp.Importer: Afree Pharmaceutical Distribution Corp. | DRP-12666-02 | Sep 22, 2027 | |
TrifexTranexamic Acid | 100 mg/mL (500 mg/5 mL) Solution for Intravenous InjectionUSP Type I Flint Glass Ampoule x 5 mL (Box of 5's) | Rx | Gufic Biosciences LimitedIndia | Ambica International Corporation | DRP-5172 | Feb 13, 2029 | |
TriqoxTranexamic Acid | 100 mg/mL Solution For Injection (IV/IM)USP Type I Clear Glass Ampoule x 5 mL (Box of 10 ampoules in PVC tray) | Rx | Indus Pharma (Pvt.) Ltd.Pakistan | AMEDIQO PHILS., INC.Importer: One Dexcel Pharma Inc. | DRP-11171-01 | Feb 8, 2027 | |
UnbrandedTranexamic Acid | 100 mg/mL Solution for Intravenous InjectionUSP Type I clear glass ampoule x 5 mL in plastic tray (Box of 5’s) | Rx | Akums Drugs & Pharmaceuticals Ltd. (Plant III - Injectables)India | Ritemed Phils., Inc.Importer: Ambica International CorporationTrader: Unosource Pharma Limited | DRP-11399 | Mar 8, 2032 | |
UnotationTranexamic Acid | 500 mg/5 mL (100 mg/mL) Solution for Injection (IV)5 mL USP Type I Clear and Colorless Glass Ampoule in PVC Tray (Box of 5's) | Rx | Akums Drugs & Pharmaceuticals Ltd (Plant III - Injectables)India | SMHP Pharmaceuticals IncorporatedTrader: Unosource Pharma Ltd | DRP-10574 | Oct 18, 2031 | |
VasocoolTranexamic Acid | 100 mg/mL (500 mg/5 mL) Solution for Injection (IM/IV)USP Type I clear glass ampoule x 5 mL in PVC plastic tray (Box of 5's) | Rx | Farbe FirmaIndia | AMB HK Enterprises Inc. | DRP-13797 | May 2, 2028 | |
XanilTranexamic Acid | 100 mg/mL Solution for Injection (IV)Low Borosilicate Glass Ampoule x 5 mL (Box of 5's and 10's) | Rx | Reyoung Pharmaceutical Co., Ltd.China | AMB HK Enterprises Inc. | DRP-17004 | Sep 4, 2030 | |
XedTranexamic Acid | 100 mg/mL Solution for Injection (IV/IM)USP Type I Clear Glass Ampoule x 5 mL (Box of 10 ampoules in PVC tray) | Rx | Indus Pharma (Pvt.) Ltd.Pakistan | One Dexcel Pharma Inc. | DRP-11171 | Oct 18, 2028 | |
ZetranexTranexamic Acid | 500 mg CapsulePVC Blister Pack x 10's (Box of 100's) | Rx | Azarias Pharmaceutical Laboratories Inc.Philippines | Hale Medipoint Corp. | DRP-4204-05 | Feb 8, 2028 | |
(no brand name)Tranexamic Acid | 100 mg/mL (500 mg/mL) Solution for Injection (IV)USP Type I clear glass ampoule x 5 mL (net conten) in a plastic tray (Box of 5's) | Rx | Skymap Healthcare Pvt. Ltd.India | Medinova Pharmacuetical Inc. | DRP-15874 | Sep 25, 2029 | |
(no brand name)Tranexamic Acid | 100 mg/mL Solution for Injection (I.V.)USP Type I Flint Glass Ampoule with Yellow Dot OPC x 5 mL (Box of 5's) | Rx | Samrudh Pharmaceuticals Pvt. Ltd.India | I.E. Medica, Inc.Trader: Alvita Pharma Pvt. Ltd. | DRP-15667 | Aug 16, 2029 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
United States (label)
Dosage forms and strengths (US label) US FDA label
3 DOSAGE FORMS AND STRENGTHS Injection: 1,000 mg/10 mL (100 mg/mL) clear and colorless solution in single-dose ampules Injection: 1,000 mg/10 mL (100 mg/mL) clear and colorless solution in single-dose vials • Injection: 1,000 mg/10 mL (100 mg/mL) in single-dose ampules (3) • Injection: 1,000 mg/10 mL (100 mg/mL) in single-dose vials (3)
Warnings/Precautions
The boxed warning is shown at the top of this page.
- • Risk of Thrombosis with Concomitant Use of Factor IX: Avoid concomitant use. (5.2)
- • Seizures: Inadvertent injection into neuraxial system may result in seizures. (5.3)
- • Hypersensitivity Reactions: In case of severe reaction, discontinue use and seek immediate medical attention. (5.4)
- • Visual Disturbances: Visual or ocular adverse effects may occur. Discontinue use if visual or ocular symptoms occur. (5.5)
- • Dizziness: Advise patients not to drive if dizziness occurs. (5.6)
5.1 Risk of Medication Errors Due to Incorrect Route of Administration
5.1 Risk of Medication Errors Due to Incorrect Route of Administration CYKLOKAPRON is for intravenous use only. Serious, including fatal, adverse reactions including seizures and cardiac arrythmias have occurred when CYKLOKAPRON was inadvertently administered via the neuraxial route. Confirm the correct route of administration for CYKLOKAPRON and avoid confusion with other injectable solutions that might be administered at the same time as CYKLOKAPRON.
Clearly label syringes containing CYKLOKAPRON with the intravenous route of administration.
5.2 Thromboembolic Risk
5.2 Thromboembolic Risk CYKLOKAPRON is contraindicated in patients with active intravascular clotting. Tranexamic acid is an antifibrinolytic and may increase the risk of thromboembolic events. Venous and arterial thrombosis or thromboembolism has been reported in patients treated with CYKLOKAPRON. Avoid concomitant use of CYKLOKAPRON and medical products that are pro-thrombotic, as the risk of thrombosis may be increased.
These medications include but are not limited to, Factor IX Complex concentrates, Anti-inhibitor Coagulant concentrates, and hormonal contraceptives [see Drug Interactions (7.1), Use in Specific Populations (8.3)].
5.3 Seizures
5.3 Seizures CYKLOKAPRON may cause seizures, including focal and generalized seizures. The most common setting for tranexamic acid-induced seizures has been during cardiovascular surgery (a setting in which CYKLOKAPRON is not FDA‑approved and which uses doses of up to 10‑fold higher than the recommended human dose and in patients inadvertently given tranexamic acid via the neuraxial route).
CYKLOKAPRON is contraindicated for neuraxial administration (i.e., epidural, intrathecal). Consider dose reduction during surgery and dose adjustments for patients with clinical conditions such as renal dysfunction. Closely monitor the patient during surgery. Consider electroencephalogram (EEG) monitoring for patients with history of seizures or who experience myoclonic movements, twitching, or show evidence of focal seizures.
Discontinue CYKLOKAPRON if seizures occur.
5.4 Hypersensitivity Reactions
5.4 Hypersensitivity Reactions Cases of hypersensitivity reactions, including anaphylactic reactions, have occurred with use of intravenous tranexamic acid. Discontinue treatment with CYKLOKAPRON if serious reaction occurs, provide appropriate medical management, and do not restart treatment. CYKLOKAPRON is contraindicated in patients with a history of hypersensitivity to tranexamic acid.
5.5 Visual Disturbances
5.5 Visual Disturbances Although not seen in humans, focal areas of retinal degeneration have been observed in cats and dogs following oral or intravenous tranexamic acid at doses between 250 to 1600 mg/kg/day (1.6 to 22 times the recommended usual human dose based on body surface area) from 6 days to 1 year. No retinal changes have been observed in eye examinations of patients treated with tranexamic acid for up to 8 years.
Patients expected to be treated for greater than 3 months may consider ophthalmic monitoring including visual acuity and optical coherence tomography at regular intervals. Discontinue CYKLOKAPRON if changes in ophthalmological examination occurs.
5.6 Dizziness
5.6 Dizziness CYKLOKAPRON may cause dizziness. Concomitant use of other drugs that may also cause dizziness may worsen this effect. Advise patients to avoid driving or using machines until they know how CYKLOKAPRON affects them.
Drug interactions
Drug interactions (US label) US FDA label
7 DRUG INTERACTIONS Prothrombotic Medical Products: Avoid concomitant use, can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid. (5.2, 7.1, 8.3) 7.1 Prothrombotic Medical Products Avoid concomitant use of CYKLOKAPRON with medical products that are prothrombotic because concomitant use can further increase the risk of thromboembolic adverse reactions associated with tranexamic acid [see Warnings and Precautions (5.2), Use in Specific Populations (8.3)].
Adverse reactions
Adverse reactions (US label) US FDA label
6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling:
- Risk of Medication Errors Due to Incorrect Route of Administration [see Warnings and Precautions (5.1)]
- Thromboembolic Risk [see Warnings and Precautions (5.2)]
- Seizures [see Warnings and Precautions (5.3)]
- Hypersensitivity Reactions [see Warnings and Precautions (5.4)]
- Visual Disturbances [see Warnings and Precautions (5.5)]
- Dizziness [see Warnings and Precautions (5.6)] Most common adverse reactions are nausea, vomiting, diarrhea, allergic dermatitis, giddiness, hypotension, and thromboembolic events. (6) To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.2 Postmarketing Experience The following adverse reactions have been identified during postapproval use of tranexamic acid. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Gastrointestinal disturbances (nausea, vomiting, diarrhea) may occur and may resolve with dose-reduction. Allergic dermatitis and giddiness have been reported. Hypotension has been reported when intravenous injection is too rapid. Thromboembolic events (e.g., deep vein thrombosis, pulmonary embolism, cerebral thrombosis, acute renal cortical necrosis, and central retinal artery, vein obstruction and cases associated with concomitant use of combination hormonal contraceptives) have been rarely reported in patients receiving tranexamic acid for indications other than hemorrhage prevention in patients with hemophilia. Convulsion, chromatopsia, and visual impairment have also been reported. Anaphylaxis or anaphylactoid reactions have been reported that are suggestive of a causal relationship.
Pregnancy considerations
Pregnancy (US label) US FDA label
8.1 Pregnancy Risk Summary Available data from published studies, case series and case reports with tranexamic acid use in pregnant women in the second and third trimester and at the time of delivery have not clarified whether there is a drug-associated risk of miscarriage or adverse maternal or fetal outcomes. There are 2 (0.02%) infant cases with structural abnormalities that resulted in death when tranexamic acid was used during conception or the first trimester of pregnancy; however, due to other confounding factors the risk of major birth defects with use of tranexamic acid during pregnancy is not clear.
Tranexamic acid is known to pass the placenta and appears in cord blood at concentrations approximately equal to maternal concentration (see Data). Reproduction studies performed in mice, rats, and rabbits have not revealed any adverse effects on the fetus due to tranexamic acid administered during organogenesis. Doses examined were multiples of up to 3 times (mouse), 6 times (rat), and 3 times (rabbit) the maximum human dose based on body surface area in the mouse, rat, and rabbit, respectively (see Data).
The estimated background risk for major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in the clinically recognized pregnancies is 2–4% and 15–20%, respectively.
It is not known whether tranexamic acid use in pregnant women may cause a drug-associated risk of miscarriage or adverse maternal or fetal outcomes. For decisions regarding the use of CYKLOKAPRON during pregnancy, the potential risk of CYKLOKAPRON administration on the fetus should always be considered along with the mother's clinical need for CYKLOKAPRON; an accurate risk-benefit evaluation should drive the treating physician's decision.
Data Human Data Tranexamic acid passes through the placenta. The concentration in cord blood after an intravenous injection of 10 mg/kg to pregnant women is about 30 mg/L, as high as in the maternal blood. There were 13 clinical studies that described fetal and/or neonatal functional issues such as low Apgar score, neonatal sepsis, cephalohematoma and 9 clinical studies that discussed alterations to growth including low birth weight and preterm birth at 22–36 weeks of gestation in fetuses and infants exposed to tranexamic acid in-utero.
Animal Data In embryo-fetal development studies, tranexamic acid was administered to pregnant mice from Gestation Day (GD) 6 through GD 12 and rats from GD 9 through GD 14 at daily doses of 0.3 or 1.5 g/kg. There was no evidence of adverse developmental outcomes in mice and rats at multiple of 3 and 6 times the maximum recommended human dose based on body surface area in the mouse and rat, respectively.
In rabbits, tranexamic acid was administered intravenously at doses of 50, 100, or 200 mg/kg/day or orally at doses of 100, 200, or 400 mg/kg/day from GD 6 through GD 18. There was no evidence of adverse developmental outcomes at dose multiples of 2 or 3 times, respectively, the maximum recommended human dose based on body surface area.
Intravenous doses of 200 mg/kg/day showed slightly retarded weight gain in pregnant rabbits.
Mechanism of action
12.1 Mechanism of Action Tranexamic acid is a synthetic lysine amino acid derivative, which diminishes the dissolution of hemostatic fibrin by plasmin. In the presence of tranexamic acid, the lysine receptor binding sites of plasmin for fibrin are occupied, preventing binding to fibrin monomers, thus preserving and stabilizing fibrin's matrix structure.
The antifibrinolytic effects of tranexamic acid are mediated by reversible interactions at multiple binding sites within plasminogen. Native human plasminogen contains 4 to 5 lysine binding sites with low affinity for tranexamic acid (Kd = 750 μmol/L) and 1 with high affinity (Kd = 1.1 μmol/L). The high affinity lysine site of plasminogen is involved in its binding to fibrin.
Saturation of the high affinity binding site with tranexamic acid displaces plasminogen from the surface of fibrin. Although plasmin may be formed by conformational changes in plasminogen, binding to and dissolution of the fibrin matrix is inhibited.
US FDA labelPharmacodynamics
Pharmacodynamics (US label) US FDA label
12.2 Pharmacodynamics Tranexamic acid, in concentrations of 1 mg/mL and 10 mg/mL prolongs the thrombin time. An antifibrinolytic concentration of tranexamic acid remains in different tissues for about 17 hours, and in the serum, up to 7 or 8 hours. Tranexamic acid in concentrations up to 10 mg/mL blood has no influence on the platelet count, the coagulation time or various coagulation factors in whole blood or citrated blood from healthy subjects.
Pharmacokinetics
Elimination After an intravenous dose of 1 g, the plasma concentration time curve shows a triexponential decay with a half-life of about 2 hours for the terminal elimination phase.
Excretion Urinary excretion is the main route of elimination via glomerular filtration.
Overall renal clearance is equal to overall plasma clearance (110 to 116 mL/min), and more than 95% of the dose is excreted in the urine as unchanged drug.
Excretion of tranexamic acid is about 90% at 24 hours after intravenous administration of 10 mg/kg body weight.
Urinary excretion following a single intravenous injection of tranexamic acid declines as renal function decreases.
Pharmacokinetics (US label) US FDA label
12.3 Pharmacokinetics Distribution The initial volume of distribution is about 9 to 12 liters. The plasma protein binding of tranexamic acid is about 3% at therapeutic plasma levels and seems to be fully accounted for by its binding to plasminogen. Tranexamic acid does not bind to serum albumin. Elimination After an intravenous dose of 1 g, the plasma concentration time curve shows a triexponential decay with a half-life of about 2 hours for the terminal elimination phase.
Excretion Urinary excretion is the main route of elimination via glomerular filtration. Overall renal clearance is equal to overall plasma clearance (110 to 116 mL/min), and more than 95% of the dose is excreted in the urine as unchanged drug. Excretion of tranexamic acid is about 90% at 24 hours after intravenous administration of 10 mg/kg body weight.
Specific Populations Patients with Renal Impairment The blood levels of tranexamic acid are increased in patients with renal insufficiency. Urinary excretion following a single intravenous injection of tranexamic acid declines as renal function decreases. Following a single 10 mg/kg intravenous injection of tranexamic acid, the 24-hour urinary fractions of tranexamic acid with serum creatinine concentrations 1.4 – 2.8, 2.8 – 5.7, and greater than 5.7 mg/dL were 51, 39, and 19%, respectively.
The 24-hour tranexamic acid plasma concentrations for these patients demonstrated a direct relationship to the degree of renal impairment. Therefore, dose adjustment is needed in patients with renal impairment [see Dosage and Administration (2.2), Use in Specific Populations (8.6)]. Drug Interaction Studies No studies of interactions between CYKLOKAPRON and other drugs have been conducted.
Formulary and pricing (Philippines)
Government price references
| Preparation | Price (PHP) | Unit | Type |
|---|---|---|---|
| Tranexamic Acid 100 mg/mL, 5 mL Ampule | ₱12.22–₱950.00Reference ₱14.32 | per ampule | DPRI procurement range |
| Tranexamic Acid 500 mg Capsule | ₱3.48–₱15.00Reference ₱5.38 | per capsule | DPRI procurement range |
| Tranexamic Acid 500 mg Tablet | ₱5.00–₱5.90Reference ₱5.63 | per tablet | DPRI procurement range |
Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)
These are government procurement and reimbursement references, not retail prices. Sources:
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf, as of September 17, 2021
Formulary and coverage
| Philippine National Formulary | Listed as Tranexamic Acid |
| PNF listing | Oral: 250 mg and 500 mg capsule 500 mg tablet |
| PNF listing | Inj.: 100 mg/mL, 2.5 mL and 5 mL ampul (IM, IV) |
| PhilHealth GAMOT | No |
Sources:
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf, as of November 2, 2022
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. Cyklokapron · Pfizer Laboratories Div Pfizer Inc [US FDA-approved label, version 34, September 3, 2025]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6e89a7d9-4da4-42aa-b7f8-c602c24eefe5
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .